AAMU
EGRX

Amundi Asset Management US’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Amundi Asset Management US’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,700
Closed -$471 – 1694
2018
Q4 		$471 Sell
11,700
-11,500
-50% -$593K ﹤0.01% 1274
2018
Q3 		$1.61M Buy
+23,200
New +$1.76M ﹤0.01% 1176

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Amundi Asset Management US's EGRX Position: Q1 2019 in Review

Amundi Asset Management US sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 11,700 shares — an estimated $471 sold.

Amundi Asset Management US first reported a position in EGRX in Q3 2018 and held it in 2 quarters. The position peaked at $1.61M in Q3 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

  • Amundi Asset Management US reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 11,700 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $471.
  • Amundi Asset Management US first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 2 quarters.
  • Amundi Asset Management US's Eagle Pharmaceuticals, Inc. position peaked at $1.61M in Q3 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Amundi Asset Management US's 13F filing for Q1 2019, filed 13 May 2019.